Informations générales (source: ClinicalTrials.gov)
Research of Anatomo-functional Biomarkers in Schizophrenia (CLOZAREST)
Observational
University Hospital, Caen (Voir sur ClinicalTrials)
avril 2019
octobre 2021
29 juin 2024
To objectify UR biomarkers, we propose a longitudinal follow-up of resistant patients
with schizophrenia, starting before the onset of clozapine and including a multimodal
brain imaging assessment (T1 and T2 weighted sequences, DTI, ASL-Perfusion, fMRI- Rest)
associated with clinical and biological monitoring. In order to correct the MRI signal of
clozapine hemodynamic effects, we will develop a new MRI methodology based on the
concomitant collection of physiological parameters (blood pressure, electrocardiogram and
respiration).
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU CAEN Normandie - 14000 - Caen - Normandie - France | Anaïs Vandevelde, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- schizophrenia or schizoaffective disorder (DSM 5)
- drug resistance
- written patient approval
- social security number in France
- curator or tutor approval if needed
- schizophrenia or schizoaffective disorder (DSM 5)
- drug resistance
- written patient approval
- social security number in France
- curator or tutor approval if needed
- pregnancy
- other research participation
- neurological evolution disorder
- no MRI contraindication